<DOC>
	<DOC>NCT00868816</DOC>
	<brief_summary>The purpose of this study is to investigate which oxaliplatie based adjuvant method (8 cycles or 12 cycles) is better for patients receiving curative colorectal cancer resection.</brief_summary>
	<brief_title>Oxaliplatine Based Adjuvant Chemotherapy for Stage II/III Colorectal Cancer: 8 Cycles Versus 12 Cycles</brief_title>
	<detailed_description>We administered 5-FU, lv and Oxaliplatin as adjuvant chemotherapy (3 weeks per cycle) to patients with Stage II or Stage III colorectal cancer. The study endpoints were disease-free survival, overall survival, and liver metastasis-free survival as evaluated by intent-to-treat analysis.</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>age &lt; 75 years with histologically proven adenocarcinoma of the colon or rectum no severe major organ dysfunction WHO performance status of 0 or 1 Stage II (T34, N0, M0) or Stage III (T04, N12, M0) disease (according to the 1997 revision of the International Union Against Cancer TNM staging system) age &gt;= 75 severe major organ dysfunction WHO performance status of &gt;1 Stage I or Stage IV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>oxaliplatine</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>chemotherapy</keyword>
</DOC>